Literature DB >> 16531417

Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies.

Mariko Taniguchi1, Hiroki Kurahashi, Satoru Noguchi, Takayasu Fukudome, Takeshi Okinaga, Toshifumi Tsukahara, Youichi Tajima, Keiichi Ozono, Ichizo Nishino, Ikuya Nonaka, Tatsushi Toda.   

Abstract

Recent studies have revealed an association between post-translational modification of alpha-dystroglycan (alpha-DG) and certain congenital muscular dystrophies known as secondary alpha-dystroglycanopathies (alpha-DGpathies). Fukuyama-type congenital muscular dystrophy (FCMD) is classified as a secondary alpha-DGpathy because the responsible gene, fukutin, is a putative glycosyltransferase for alpha-DG. To investigate the pathophysiology of secondary alpha-DGpathies, we profiled gene expression in skeletal muscle from FCMD patients. cDNA microarray analysis and quantitative real-time polymerase chain reaction showed that expression of developmentally regulated genes, including myosin heavy chain (MYH) and myogenic transcription factors (MRF4, myogenin and MyoD), in FCMD muscle fibers is inconsistent with dystrophy and active muscle regeneration, instead more of implicating maturational arrest. FCMD skeletal muscle contained mainly immature type 2C fibers positive for immature-type MYH. These characteristics are distinct from Duchenne muscular dystrophy, suggesting that another mechanism in addition to dystrophy accounts for the FCMD skeletal muscle lesion. Immunohistochemical analysis revealed morphologically aberrant neuromuscular junctions (NMJs) lacking MRF4 co-localization. Hypoglycosylated alpha-DG indicated a lack of aggregation, and acetylcholine receptor (AChR) clustering was compromised in FCMD and the myodystrophy mouse, another model of secondary alpha-DGpathy. Electron microscopy showed aberrant NMJs and neural terminals, as well as myotubes with maturational defects. Functional analysis of NMJs of alpha-DGpathy showed decreased miniature endplate potential and higher sensitivities to d-Tubocurarine, suggesting aberrant or collapsed formation of NMJs. Because alpha-DG aggregation and subsequent clustering of AChR are crucial for NMJ formation, hypoglycosylation of alpha-DG results in aberrant NMJ formation and delayed muscle terminal maturation in secondary alpha-DGpathies. Although severe necrotic degeneration or wasting of skeletal muscle fibers is the main cause of congenital muscular dystrophies, maturational delay of muscle fibers also underlies the etiology of secondary alpha-DGpathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531417     DOI: 10.1093/hmg/ddl045

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Loss of synaptic vesicles from neuromuscular junctions in aged MRF4-null mice.

Authors:  Qingbo Wang; Sadie L Hebert; Mark M Rich; Susan D Kraner
Journal:  Neuroreport       Date:  2011-03-09       Impact factor: 1.837

Review 2.  Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes.

Authors:  Naosuke Nakamura; Dmitry Lyalin; Vladislav M Panin
Journal:  Semin Cell Dev Biol       Date:  2010-04-01       Impact factor: 7.727

Review 3.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis.

Authors:  Motoi Kanagawa; Tatsushi Toda
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

4.  A homozygous mutation in GMPPB leads to centronuclear myopathy with combined pre- and postsynaptic defects of neuromuscular transmission.

Authors:  Stefan Nicolau; Teerin Liewluck; Xin-Ming Shen; Duygu Selcen; Andrew G Engel; Margherita Milone
Journal:  Neuromuscul Disord       Date:  2019-07-05       Impact factor: 4.296

5.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

6.  Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.

Authors:  Aaron M Beedle; Amy J Turner; Yoshiaki Saito; John D Lueck; Steven J Foltz; Marisa J Fortunato; Patricia M Nienaber; Kevin P Campbell
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

7.  Aberrant development of neuromuscular junctions in glycosylation-defective Large(myd) mice.

Authors:  Ruth Herbst; Thomas Iskratsch; Ewald Unger; Reginald E Bittner
Journal:  Neuromuscul Disord       Date:  2009-04-05       Impact factor: 4.296

8.  Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy.

Authors:  Alison G Compton; Douglas E Albrecht; Jane T Seto; Sandra T Cooper; Biljana Ilkovski; Kristi J Jones; Daniel Challis; David Mowat; Barbara Ranscht; Melanie Bahlo; Stanley C Froehner; Kathryn N North
Journal:  Am J Hum Genet       Date:  2008-11-20       Impact factor: 11.025

9.  Disruption of basal lamina components in neuromotor synapses of children with spastic quadriplegic cerebral palsy.

Authors:  Karyn G Robinson; Janet L Mendonca; Jaimee L Militar; Mary C Theroux; Kirk W Dabney; Suken A Shah; Freeman Miller; Robert E Akins
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.

Authors:  Motoi Kanagawa; Akemi Nishimoto; Tomohiro Chiyonobu; Satoshi Takeda; Yuko Miyagoe-Suzuki; Fan Wang; Nobuhiro Fujikake; Mariko Taniguchi; Zhongpeng Lu; Masaji Tachikawa; Yoshitaka Nagai; Fumi Tashiro; Jun-Ichi Miyazaki; Youichi Tajima; Shin'ichi Takeda; Tamao Endo; Kazuhiro Kobayashi; Kevin P Campbell; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2008-11-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.